Factor VIII gene therapy - Novartis

Drug Profile

Factor VIII gene therapy - Novartis

Alternative Names: Haemophilia A gene therapy - Novartis

Latest Information Update: 19 Jul 2010

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Novartis
  • Class Blood coagulation factors; Coagulants
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Haemophilia A

Most Recent Events

  • 20 Apr 2006 Chiron Corporation has been acquired and merged into Novartis
  • 17 Dec 2003 Data presented at the 45th Annual Meeting of the American Society of Hematology (ASH-2003) have been added to the Haematological disorders therapeutic trials section
  • 28 Oct 2003 A clinical study has been added to the adverse events and pharmacokinetic sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top